From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”的候选者,转变为买家自身采购、报销、处方集、规格、采购、网络、目录或计划系统中的“已批准、指定、列入、合格、注册、报销或预授权”选择,从而使得公司未来业务的重要部分可以在没有每次单独销售事件的情况下到来,并且管理层传达这种准入状态是新的,以至于它解锁的大部分量仍在前方。 在记录中,管理层讨论了: - 公司继续增长,但未提及任何具体的“批准供应商名单”、“首选供应商名单”、“报销目录”、“处方集”等。 - 他们提到了“代理推荐计划”、“免费终身”计划,以及“修订的代理佣金结构”,但这些是内部激励措施,不是买家侧的系统准入。 - 他们提到了“LiveBy”技术,但那是向其他经纪公司授权软件,不是买家侧的系统。 - 没有提到任何政府或保险公司的批准、列入名单、报销资格等。 因此,没有描述这种“从候选到默认”的转变。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.